You are here: Industry Insights > Pharma in China > Second ADC Therapeutic Drug Was Approved for Marketing in China

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Second ADC Therapeutic Drug Was Approved for Marketing in China

CPhI.CNMay 14, 2020

Tag: ADC , antibody , NMPA

Favorites

By Xiaoyaowan

On May 13, the official website of NMPA showed that Takeda Pharmaceutical's application of vebutuximab for injection has been approved and became the second ADC drug approved in the Chinese market.

In 2011, vebutuximab for injection was approved by the FDA to be marketed in the United States under the trade name Adcetris. The launch of this drug created three records: The only currently marketed antibody conjugated drug targeting CD30, the first new anaplastic large cell lymphoma (ALCL) drug approved by the FDA in 40 years and the first first-line treatment for classic Hodgkin lymphoma (cHL) and peripheral T-cell lymphoma (PTCL).

Currently, vebuzumab has approved a variety of indications in the United States, including classic Hodgkin's lymphoma (cHL), anaplastic large cell lymphoma (ALCL) and peripheral T cell lymphoma (PTCL) and mycosis Granuloma (MF), etc. If you are looking for medical health supplies of vebuzumab, then Pharmasources would be your best choice.

The FDA approved a total of 6 ADC drugs for marketing. According to statistics, more than 60 ADC projects in the world have entered the stage of clinical research. The indications involved include urothelial cancer, triple negative breast cancer, HER2-positive breast cancer, glioblastoma, etc.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.

Previous:Exyte and Univercells Technologies combine forces for rapid deployment of vaccine production plants

Next:India calls upon G-20 nations to ensure access to essential medicines, treatments and vaccines at af

China's Innovative Drugs Hunt for Billion Dollar Molecule

XiaobinDecember 20, 2024

The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

YiDecember 20, 2024

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

XiaobinDecember 20, 2024

Second ADC Therapeutic Drug Was Approved for Marketing in China | Pharmasources.com

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

xiaobinDecember 20, 2024

Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.

Second ADC Therapeutic Drug Was Approved for Marketing in China

Related News

China's Innovative Drugs Hunt for Billion Dollar Molecule

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

You may like
More>>

Second ADC Therapeutic Drug Was Approved for Marketing in China

Related News

China's Innovative Drugs Hunt for Billion Dollar Molecule

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

You may likeMore>>

You may like
More>>